Welcome to our dedicated page for Zentek Ltd. news (Ticker: ZTEK), a resource for investors and traders seeking the latest updates and insights on Zentek Ltd. stock.
Zentek Ltd. (Nasdaq: ZTEK, TSX-V: ZEN) is an intellectual property development and commercialization company focusing on next-generation healthcare solutions for prevention, detection, and treatment. Zentek is at the forefront of commercializing ZENGuard, a groundbreaking coating with 99% antimicrobial effectiveness, including activity against COVID-19. This technology has applications in a variety of fields, including surgical masks and HVAC systems.
The company operates a state-of-the-art production facility in Guelph, Ontario, and is ISO 13485:2016 certified. Zentek has developed a synergistic relationship with McMaster University to leverage an exclusive global license for their aptamer-based rapid pathogen detection technology. This partnership has led to promising results, including the C19HBA aptamer, which has shown therapeutic potential against SARS-CoV-2, outperforming leading monoclonal antibodies in preclinical trials.
Through its wholly-owned subsidiary Triera Biosciences Ltd., Zentek continues to advance its aptamer technology. Notably, their C19HBA aptamer has demonstrated robust preclinical efficacy in both prophylactic and therapeutic settings against various SARS-CoV-2 variants, including Omicron XBB 1.5. The company is now moving towards Phase 1 clinical trials and exploring further applications for their platform in infectious diseases and oncology.
In addition to healthcare, Zentek has made significant strides in the HVAC industry. The company's ZenGUARD™ Enhanced Air Filters aim to improve air quality without increasing energy consumption or emissions. Zentek's commitment to innovation is further evidenced by a series of partnerships and distribution agreements, including collaborations with Medwell Solutions LLC and DCL Supply Ltd. These partnerships aim to expand the market reach of Zentek's antimicrobial technologies.
Recent Achievements:
- Significant progress in preclinical trials for C19HBA aptamer as a therapeutic for SARS-CoV-2.
- A promising safety and toxicity profile for the C19HBA aptamer in preclinical tests.
- Exclusive distribution agreements for ZenGUARD™ Enhanced Surgical Masks in the U.S. with Medwell Solutions LLC and DCL Supply Ltd.
- Launch preparations for ZenGUARD™ Enhanced Air Filters in the HVAC market.
- Second patent for their GO-Ag+ nanocomposite as an antimicrobial agent, expanding its potential applications to both human and veterinary medicine.
Zentek continues to focus on commercializing its proprietary technologies, aiming to provide significant health benefits while also addressing environmental concerns. By offering innovative, safer, and greener products, Zentek seeks to give its commercial partners a competitive edge in their respective markets.
Zentek Ltd. (Nasdaq:ZTEK, TSX-V:ZEN) has announced successful tests of its patent-pending Icephobic Coatings at the NRC and AMIL. Results indicate the coatings have a low adhesion ice removal capability, with shear stress remaining below 100 kPa, and effective performance in preventing ice accretion on drones and wind turbines. Notable findings include 1,000 hours of UV exposure showing slight adhesion increase and promising results in sand and rain erosion tests. Zentek aims to address significant ice accretion challenges with this technology, supported by a full patent application filed in August 2022.
Zentek Ltd. (NASDAQ:ZTEK) announced the successful completion of Phase 1 testing for its ZenGUARD™-coated HVAC filters under the Innovation Solutions Canada contract. The tests confirmed a 99% reduction in airborne pathogens without airflow reduction or significant shedding of the coating. CEO Greg Fenton emphasized the technology's potential for improving indoor air quality while maintaining energy efficiency. The company is now advancing to Phase 2 testing in a modular classroom setting to further validate its findings.
Zentek Ltd. (Nasdaq:ZTEK) has announced its 2022 Annual General and Special Meeting to take place on September 29th at 4:00 PM at the Delta Hotel, Guelph, Ontario. Attendance requires registration via email, and the event will also be live-streamed. Shareholders will vote on key items including the appointment of auditors, election of directors, and adoption of a long-term incentive plan. The management information circular will be mailed to shareholders shortly. Zentek focuses on innovative healthcare solutions, particularly antimicrobial coatings and rapid pathogen detection technology.
Zentek Ltd. (NASDAQ: ZTEK) has announced a Manufacturing and Supply Agreement with Viva Healthcare Packaging (Canada) Ltd. to produce surgical masks enhanced with Zentek's proprietary ZenGUARD™ antimicrobial coating. VMedCare, a leader in surgical mask manufacturing, will utilize Zentek's materials to create a fully Made in Canada source of these enhanced masks. This partnership aims to boost sales and meet growing demand, especially as Zentek opens its production facility in Guelph, Ontario.
Zentek Ltd. (Nasdaq:ZTEK, TSX-V:ZEN) has filed a provisional patent for its ZenGUARD™ technology as an anti-inflammatory agent for various dermatological conditions. CEO Greg Fenton emphasized their commitment to patenting and commercialization of ZenGUARD™, which is already authorized by Health Canada as an antimicrobial for surgical masks and PPE. Current research aims to explore its potential for treating conditions like acne, psoriasis, and eczema. The company is collaborating with Vimta Labs for pre-clinical data needed for FDA drug submission.
Zentek Ltd. (NASDAQ:ZTEK) announced the appointment of Ilse Treurnicht to its Board of Directors. Treurnicht, who holds a DPhil in chemistry from Oxford, is the Managing Partner of TwinRiver Capital and has significant Board-level experience, including her role as CEO of the MaRS Discovery District. She has been awarded 250,000 options at $2.44, with a vesting schedule over five years. Zentek focuses on innovative healthcare solutions, including its ZenGUARD antimicrobial coating and exclusive rights to a rapid pathogen detection technology.
Zentek Ltd. (NASDAQ:ZTEK) has initiated the Canadian national phase for its ZenGUARD™ patent application as of March 28, 2022. This technology aims to enhance personal protective equipment and HVAC systems. A second patent application focused on ZenGUARD™ as an antimicrobial treatment is set to publish on June 20, 2022, with 58 of 64 claims deemed patentable. Additionally, Zentek filed for a manufacturing process patent on April 12, 2022, aimed at reducing costs. CEO Greg Fenton emphasized the company's commitment to protecting its innovations to ensure long-term shareholder value.
Zentek Ltd. (NASDAQ: ZTEK) announced the grand opening of its industrial-scale ZenGUARD antimicrobial production facility in Guelph, Ontario, scheduled for June 17, 2022. This facility is among the largest in the world for nanomaterials-based manufacturing and supports Zentek's trajectory from laboratory to commercial success. ZenGUARD is a patent-pending coating with 99% antimicrobial effectiveness, targeting the growing demand for transmission prevention products. The company is also exploring applications in the HVAC market to generate additional revenue.
Zentek Ltd. (NASDAQ:ZTEK; TSX-V:ZEN) announced that McMaster University received two NSERC Grants for its aptamer-based rapid detection technology. The Alliance Missions Grant totals $1,000,000, while the Idea to Innovation Grant amounts to $350,000, with Zentek contributing $140,000. These funds will further enhance the commercialization of the rapid diagnostic platform, particularly in optimizing chip synthesis and developing a universal aptamer for COVID variants. This endorsement underlines the potential of Zentek's technology in the healthcare sector.
Zentek Ltd. (Nasdaq:ZTEK) announces the appointment of Wendy Ford as the new Chief Financial Officer, effective immediately. With over 30 years of experience, she aims to optimize operations and enhance shareholder value. Brian Bosse transitions to Chief Operations Officer, further strengthening leadership during a pivotal growth phase following Zentek's recent Nasdaq listing. Additionally, Moe Deib will join as Director of Global Healthcare Sales on May 24, 2022, focusing on selling ZenGUARD™ technology. ZenGUARD™ exhibits 99% antimicrobial activity and supports Zentek's healthcare commercialization strategy.
FAQ
What is the current stock price of Zentek Ltd. (ZTEK)?
What is the market cap of Zentek Ltd. (ZTEK)?
What is Zentek Ltd. specialized in?
What is ZENGuard?
What recent advancements has Zentek made in healthcare?
Who are Zentek's key partners?
What is Triera Biosciences Ltd.?
What is the latest news about Zentek?
Where is Zentek located?
What industries does Zentek serve?
What technology platforms does Zentek use?
How can I contact Zentek for more information?
